Option chain shows key data for Nabriva Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Nabriva Therapeutics.

Nabriva Therapeutics (OTC:NBRVF) Stock, Option Chain

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

NABRIVA THERAPEUTICS NEW by Nabriva Therapeutics plc

Nabriva Therapeutics PLC

Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) has outperformed the market over the past 10 years by 1.41% on an annualized basis producing an average annual return of 12.59%. Currently, Agilent Technologies has a market capitalization of $38.44 billion. 
Buying $100 In A: If an investor had bought $100 of A stock 10 years ago, it would be worth $327.79 today based on a price of $134.60 for A at the time of writing.
<h3>Agilent Technologies's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735058734_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much You Would Have Made Owning Agilent Technologies Stock In The Last 10 Years

WIIM

EVTL

Vertical Aerospace shares are trading higher. The company announced it has finalized an investment agreement for up to $50M in new funding.

BREA

Brera Holdings Shares Resume Trade

Brera Holdings Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 52.8%

Graphjet Technology Shares Halted On Circuit Breaker To The Downside, Stock Now Up 164.3%

Over the past year, OpenAI has dropped not-so-subtle hints about its revived interest in robotics: investing in startups developing hardware and software for robots such as Figure and Physical Intelligence and rebooting its internal robotics software team, which it had disbanded four years ago. Now, OpenAI could be taking that interest to the next level. The company has recently considered developing a humanoid robot, according to two people with direct knowledge of the discussions. &nbsp;As a refresher, humanoid robots typically have two arms and two legs, distinguishing them from typical robots in a warehouse or factory that might have a single arm repeatedly performing the same task on an assembly line. Developers of humanoid robots think it will be easier for them to handle tasks in the physical world—which is tailored to humans—than it would be to change our physical environments to suit new robots. Don't get too excited yet, though: Any potential humanoid robot seems to be a lower priority for OpenAI than a number of its other technologies and products, such as its highly praised reasoning models and an agent that could help automate all manner of software engineering and analysis tasks, one of these people said.
<a href="https://www.theinformation.com/articles/openai-has-discussed-making-a-humanoid-robot" title="https://www.theinformation.com/articles/openai-has-discussed-making-a-humanoid-robot">https://www.theinformation.com/articles/openai-has-discussed-making-a-humanoid-robot</a> &nbsp;

MSFT

TSLA

'OpenAI Has Discussed Making a Humanoid Robot' - The Information

Graphjet Technology Shares Resume Trade

Brera Holdings Shares Halted On Circuit Breaker To the Upside, Stock Now Up 29.9%

According to widely-followed crypto influencer &#8216;artchick,&#8217; Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) will not be the main meme coin <a href="https://www.benzinga.com/money/bitcoin-price-prediction">beneficiaries of a rally</a>.
The influencer&#8217;s forecast hinges on Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) maintaining its momentum and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) outperforming. 
Her top five include Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) with a $1 trillion target, Mog (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MOG</a>) at $200 billion, Popcat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POPCAT</a>) and Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>) at $25 billion each. Among the newer entrant, Goatseus Maximus (CRYPTO: GOAT), Fartcoin also made it to the list. Artchick also added Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) with $25 billion price target to the list.
She says that while these valuations might feel absurd right now, crypto isn't operating on "normal cycles" anymore. "We're nearing escape velocity", and the market dynamics are evolving rapidly.
While ETH and SOL face inflation and execution risks, the meme coins traded on these chains are inherently different—they're pure, antifragile digital assets. 
By late 2025, the trader <a href="https://x.com/digitalartchick/status/1871365793596035105">believes</a> they'll be among the most sought after and resilient asset classes ever created.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42626582/dogecoin-shiba-inu-absent-from-2024s-top-performing-meme-coins-heres-who-made-the-cut">Dogecoin, Shiba Inu Absent From 2024&#8217;s Top-Performing Meme Coins: Here&#8217;s Who Made The Cut</a>
Artchick emphasizes that meme coin investing requires careful position sizing to endure high volatility and sharp drawdowns. She explains: &#8220;If you're overexposed, you're not going to make it. Volatility and shakeouts strengthen these memes. See you at the top.&#8221;
Her analysis suggests meme coins could emerge as one of the most resilient and sought-after digital asset classes by 2025.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42645811/dogecoin-shiba-inu-could-underperform-stronger-cryptos-trader-warns-heres-why">Dogecoin, Shiba Inu Could Underperform Stronger Cryptos, Trader Warns: Here&#8217;s Why</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BONK

$BTC

$DOGE

$ETH

$MOG

$PEPE

$POPCAT

$SHIB

$SOL

$WIF

Bitcoin's Outperformance Could Leave Dogecoin, Shiba Inu Sidelined, But Propel Pepe, Dogwifhat, Bonk To New Highs

Key Highlights of the Acquisition Process:
<ol>
<li>Investments and Share Purchase Agreement ("SPA") – Brera Holdings has agreed to acquire a majority stake in Juve Stabia through share capital and reserve increases in the Club.&nbsp; These will be made by Brera via cash payments and issuances of BREA's shares in a three-step process that ensures a seamless transition and continuity in club management. These three steps, upon conclusion, will give Brera Holdings 22%, 38%, and ~52% ownership of the Club. Upon completion of these three steps, Brera will be the Club's majority shareholder, and a Shareholder Agreement with the current sole owner, Andrea Langella, will further enable integration into its multi-club framework. The first step, giving Brera 22% ownership, is expected to conclude by December 31, 2024.</li>
<li>Milestone-Based Compensation – The SPA includes provisions for additional compensation to Mr. Langella tied to performance-based milestones, such as qualification for Serie B promotion playoffs and promotion to Serie A. These incentives align Brera's interests with Juve Stabia's competitive success, reinforcing a focus on operational excellence.</li>
<li>Final Closing and Majority Control – The acquisition will conclude with a third and final closing, scheduled for March 31, 2025. At that point, Brera Holdings will secure ~52% ownership, establishing Brera as the controlling shareholder and enabling immediate integration of the Club into the Company's multi-club framework. This phased approach ensures a seamless transition and continuity in Club management and prepares the Club for an IFRS audit according to the PCAOB guidelines for SEC disclosure filings.</li>
</ol>

Brera Holdings Outlines 3-Step Plan To Acquire 52% Stake In Serie B Club Juve Stabia, Integrating It Into Multi-Club Model To Drive Value Creation; Initial 22% Stake Expected By December 31, 2024, With Full Majority Control By March 2025; No Financial Terms Disclosed

Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) saw its shares rise on Tuesday after announcing that it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, a drug <a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener">targeting alcohol use disorder (AUD)</a>.
This approval marks a significant milestone in the company&#8217;s FDA-regulated clinical program, and the trial will be conducted at Yale School of Medicine&#8217;s Department of Psychiatry, led by Anahita Bassir Nia, an expert in psychiatry and addiction medicine.
The trial will evaluate the safety, tolerability, and efficacy of CMND-100, a proprietary investigational drug designed to reduce alcohol cravings and consumption in individuals with moderate to severe AUD.
Adi Zuloff-Shani, CEO of Clearmind Medicine, emphasized the importance of this step, noting that alcohol use is a leading preventable cause of death globally, responsible for 2.6 million deaths annually.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/12/42669198/whats-going-on-with-nio-stock-on-tuesday" rel="noreferrer noopener">What&#8217;s Going On With NIO Stock On Tuesday?</a>
Current treatment options are limited, with low efficacy and patient compliance.
Clearmind aims to address this gap with CMND-100, offering a potential solution for treating AUD that could significantly improve patient outcomes.
The trial is expected to provide critical data to support the advancement of CMND-100 through its clinical pipeline, offering hope for more effective treatment options for those struggling with alcohol addiction.
According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, CMND stock has lost over 6% in the past month. Investors can gain exposure to the stock via AdvisorShares Psychedelics ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSIL#NYSE">PSIL</a>).
Price Action: CMND shares are trading higher by 35% to $1.64 at last check Tuesday.
Read Action:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42664692/bitcoin-flat-ethereum-dogecoin-spike-ahead-of-christmas-analyst-says-decline-in-btc-dominance-leaves-room-for-altcoins-to-pick-up" target="_blank" rel="noreferrer noopener">Bitcoin Flat, Ethereum, Dogecoin Spike Ahead Of Christmas: Analyst Says Decline In BTC Dominance Leaves ‘Room For Altcoins To Pick Up'</a></li>
</ul>
Photo: Shutterstock

Equities

Health Care

Markets

Movers

General

CMND

PSIL

Why Is Penny Stock Clearmind Gaining Today?

Solana&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) <a href="https://www.benzinga.com/money/solana-price-prediction">growth over the past two years</a>, marked by a staggering 2,143% price increase, is rooted in a substantial $55 billion influx of new capital, according to a recent analysis by Glassnode.
The <a href="https://insights.glassnode.com/analyzing-the-movement-of-capital-across-the-solana-asset/?utm_campaign=SOL_Stage2&amp;utm_medium=email&amp;utm_source=SOL_launch">report,</a> released earlier in the week, delves into the network's underlying dynamics, revealing robust investor demand that, despite profit-taking, hasn&#8217;t reached levels traditionally associated with market tops.
Solana's journey from a low of $9.64 following the FTX collapse to its current position as a major crypto contender is a story of notable recovery. 
The Glassnode report highlights this outperformance, noting that Solana has not only eclipsed Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) in price appreciation but has also consistently attracted more capital, capturing significant market attention. 
This surge is not merely speculative; it&#8217;s backed by a tangible shift in investor preference.
The analysis reveals a critical detail: new capital flowing into Solana is outpacing that of Ethereum for the first time. 
This is measured by the &#8220;Hot Realized Cap,&#8221; which tracks capital held by newly active addresses. 
The data underscores a growing appetite for Solana, particularly among new market entrants, a factor that propelled the asset&#8217;s growth at the start of 2024. 
This surge in capital inflow shows the network&#8217;s appeal.
Glassnode&#8217;s report goes on to track the on-chain capital flow, revealing a consistent net positive inflow into Solana since September 2023. 
This consistent liquidity injection has been the backbone of Solana's price appreciation, with daily inflows peaking at $776 million.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42667932/did-vladimir-putin-just-ban-bitcoin-mining-in-russia-the-devil-is-in-the-details">Did Vladimir Putin Just Ban Bitcoin Mining In Russia? The Devil Is In The Details</a>
This indicates a healthy demand-side dynamic essential for sustaining growth.
The analysis also addresses the natural phenomenon of profit-taking that occurs during bull markets. 
Glassnode's breakdown shows a balanced distribution of profit taking across different investor cohorts, from short-term holders to those holding for longer periods of 6-12 months. 
This highlights the broad appeal of Solana as an investment for different types of market participants. 
As a result of these inflows, Solana has seen its Realized Cap rise from $22B to $77B.
Despite the rapid price increase, the report posits that the market isn&#8217;t overheated.
Using the MVRV ratio as a benchmark, the analysis notes that current investor profitability is within reasonable bounds, not yet reaching the extreme levels historically seen at market tops. 
This suggests that there is potential for further upward movement before the market becomes overextended.
Glassnode&#8217;s report portrays a market driven by solid capital inflows and a broad base of investors. 
Solana&#8217;s recovery is not just a story of price action, but also one of substantial liquidity and expanding adoption. 
While vigilance is needed, the current data suggests a sustainable growth trajectory, not an imminent bubble. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42667518/deribit-eyes-growth-in-asset-backed-crypto-with-pax-gold-debut">Deribit Eyes Growth In Asset-Backed Crypto With Pax Gold Debut</a></li>
</ul>
Image: Shutterstock

Solana Surged 2,000% In 2 Years, But It Could Go Even Higher: Report

Graphjet Technology Shares Halted On Circuit Breaker To The Upside, Stock Now Up 226%

Navitas Semiconductor's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NYSE">NVTS</a>) short percent of float has fallen 15.63% since its last report. The company recently reported that it has 23.48 million shares sold short, which is 18.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.91 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Navitas Semiconductor Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735057821_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Navitas Semiconductor has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Navitas Semiconductor's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Navitas Semiconductor's peer group average for short interest as a percentage of float is 8.82%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

NVTS

(NVTS) - Analyzing Navitas Semiconductor's Short Interest

Intellia Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NYSE">NTLA</a>) short percent of float has risen 15.57% since its last report. The company recently reported that it has 18.91 million shares sold short, which is 21.15% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.83 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Intellia Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735057816_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Intellia Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Intellia Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Intellia Therapeutics's peer group average for short interest as a percentage of float is 13.63%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

NTLA

Peering Into Intellia Therapeutics's Recent Short Interest

Ares Capital's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NYSE">ARCC</a>) short percent of float has risen 10.7% since its last report. The company recently reported that it has 17.31 million shares sold short, which is 2.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.48 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ares Capital Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735057811_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ares Capital has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ares Capital's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ares Capital's peer group average for short interest as a percentage of float is 3.15%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ARCC

Looking Into Ares Capital's Recent Short Interest

Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) has outperformed the market over the past 5 years by 7.17% on an annualized basis producing an average annual return of 20.46%. Currently, Unum Gr has a market capitalization of $13.29 billion. 
Buying $100 In UNM: If an investor had bought $100 of UNM stock 5 years ago, it would be worth $252.81 today based on a price of $72.77 for UNM at the time of writing.
<h3>Unum Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735057808_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Unum Gr 5 Years Ago Would Be Worth Today

HOUR

Hour Loop Shares Resume Trade

Contractors working on Google Gemini are comparing its responses to Claude's, according to internal correspondence seen by TechCrunch.
<a href="https://techcrunch.com/2024/12/24/google-is-using-anthropics-claude-to-improve-its-gemini-ai/" title="https://techcrunch.com/2024/12/24/google-is-using-anthropics-claude-to-improve-its-gemini-ai/">https://techcrunch.com/2024/12/24/google-is-using-anthropics-claude-to-improve-its-gemini-ai/</a>

Comments

Nabriva Therapeutics

Nabriva Therapeutics (NBRVF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga